Pharmacokinetics and tolerability of prulifloxacin after single oral administration

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 3, 2003, Pages 201-205

  Picollo, Rossella ^a,d   Brion, Nils ^b   Gualano, Virginie ^c   Millérioux, Laurette ^c   Marchetti, Marcello ^a   Rosignoli, Maria Teresa ^a   Dionisio, Paolo ^a  

^a Angelini ACRAF SPalomba Pomezia   (Italy)

^b U de Pharmacologie Clinique VERSUS   (France)

^c ASTER CEPHAC Research Centre   (France)

^d ACRAF SPA   (Italy)

Author keywords

AF3012; CAS 112984 60 8; CAS 123447 62 1; Fluoroquinolones; NM441; Prulifloxacin, clinical pharmacokinetics

Indexed keywords

AF 3012; ANTIINFECTIVE AGENT; CAS 123447 62 1; DRUG METABOLITE; PRODRUG; PRULIFLOXACIN; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FRIEDMAN TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH PAIN; URINALYSIS;

EID: 0344837329     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297095     Document Type: Article

References (12)

1. Hooper, D. C., New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30, 243 (2000)
2. Oliphant, C. M., Green, G. M., Quinolones: a comprehensive review. Am. Fam. Physician. 65, 455 (2002)
3. Schaeffer, A. J., The expanding role of fluoroquinolones. Am. J. Med. 113 (Suppl. 1A), 45S (2002)
4. Campbell, G. D. Jr, The role of antimicrobial therapy in acute exacerbations of chronic bronchitis. Am. J. Med. Sci. 318, 84 (1999)
5. Adams, S. G., Anzueto, A., Antibiotic therapy in acute exacerbation of chronic bronchitis. Semin. Respir. Infect. 15, 234 (2000)
6. Montanari, M. P., Mingoia, M., Varaldo, P. E., In vitro antibacterial activities of AF3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob. Agents Chemother. 45, 3616 (2001)
7. Prats, G., Roig, C., Mirò, E. et al., In vitro activity of AF3013, the active metabolite of prulifloxacin: a comparison with other fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. 21, 328 (2002)
8. Tougou, K., Nakamura, A., Watanabe, S. et al., Paraxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab. Dispos. 26, 355 (1998)
9. Nakashima, M., Uematsu, T., Kosuge, K. et al., Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J. Clin. Pharmacol. 34, 930 (1994)
10. Lubasch, A., Keller, I., Borner, K. et al., Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44, 2600 (2000)
11. nd Communication: Pharmacokinetics and effect on hepatic drug-metabolizing activities after repeated administration and transfer into fetus and milk after a single administration in rats. Arzneim.-Forsch./Drug Res. 47 (I), 285 (1997)
12. Grassi, C., Salvatori, E., Rosignoli, M. T., Dionisio, P., Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 69, 217 (2002)